# OnCo record avzo-1418 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avzo-1418/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avzo-1418" ;
  schema:name "AVZO-1418"@en ;
  schema:alternateName "DB-1418"@en, "AVZO-1418/DB-1418"@en ;
  schema:description "AVZO-1418 is an experimental antibody-drug conjugate that targets two proteins, EGFR and HER3, on cancer cells. Avenzo Therapeutics licensed it from DualityBio and is testing it in a first phase 1/2 trial in advanced solid tumours."@en ;
  schema:url <https://onco.cc/drugs/avzo-1418/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate>, <https://clinicaltrials.gov/study/NCT07038343> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Bispecific antibody-drug conjugate (EGFR x HER3, topoisomerase I inhibitor payload)" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/her3/> ;
  onco:companies <https://onco.cc/companies/avenzo/>, <https://onco.cc/companies/dualitybio/> ;
  onco:trials <https://onco.cc/trials/nct07038343/> .